NCT06160622View on ClinicalTrials.gov

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Kidney Impairment
Interventions
DRUG

Leritrelvir

Oral

Trial Locations (1)

Unknown

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT06160622 - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease | Biotech Hunter | Biotech Hunter